Karuna plunders Goldfinch`s nest to pad neuroscience pipeline
03 Feb 2023 //
FIERCE BIOTECH
Goldfinch Bio has its wings clipped, shutting down after 7 years
27 Jan 2023 //
FIERCE BIOTECH
Goldfinch Bio`s Publication in Science Advances on Human Derived Organoids
07 Jul 2022 //
BUSINESSWIRE
Goldfinch Bio to Present Initial Data from PI Trial of GFB-024 at ADA & ENDO
31 May 2022 //
BUSINESSWIRE
Goldfinch Bio to Host Virtual Event on Unmet Need in FSGS and GFB-887
22 Mar 2022 //
BUSINESSWIRE
Goldfinch`s kidney drug one-one in early phase 2 data
01 Mar 2022 //
FIERCEBIOTECH
Goldfinch Bio`s Positive Preliminary Data from Phase 2 Trial Evaluating GFB-887
28 Feb 2022 //
BUSINESSWIRE
Goldfinch Bio to Participate in Upcoming Industry Conferences
23 Feb 2022 //
BUSINESSWIRE
Goldfinch Announces Initiation of Open-Label Extension Study in Trial of GFB-887
10 Aug 2021 //
BUSINESSWIRE
Goldfinch Bio to Present at the 2021 Wedbush PacGrow
04 Aug 2021 //
BUSINESSWIRE
Goldfinch Bio Initiates Phase 1 Clinical Trial of GFB-024, a Novel Precision
13 May 2021 //
BUSINESSWIRE
Goldfinch Bio reports positive data from GFB-887 trial
23 Oct 2020 //
CLINICALTRAILSARENA
Goldfinch Bio Presents Clinical Data from Ph1 Trial Supporting of GFB-887
23 Oct 2020 //
BLOOMBERG
Goldfinch Bio Presents Data from Phase 1 Trial Supporting of GFB-887
22 Oct 2020 //
BUSINESSWIRE
GOLDFINCH BIO ANNOUNCES UPCOMING PRESENTATION OF PHASE 1 GFB-887
13 Oct 2020 //
GOLDINCHBIO
Academic and Industry Collaborative Study, including Goldfinch Bio, Benefit
08 Oct 2020 //
BUSINESSWIRE
Goldfinch Initiates Phase 2 Clinical Trial Evaluating Drug Candidate GFB-887
08 Sep 2020 //
BIOSPACE
Goldfinch Bio Secures $100 Million in Series B Financing
30 Jun 2020 //
BUSINESSWIRE
Gilead-partnered Goldfinch Bio lands $100M it pivots to clinical stage biotech
30 Jun 2020 //
ENDPTS
Goldfinch Bio & Takeda Announces Licensing Agreement for CB1 Monoclonal Antibody
04 Oct 2019 //
BIOSPACE
Gilead taps Nurix`s protein degradation tech in $45M cancer pact
19 Jun 2019 //
FIERCE BIOTECH